Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
PLoS Negl Trop Dis. 2020 Nov 3;14(11):e0008817. doi: 10.1371/journal.pntd.0008817. eCollection 2020 Nov.
The 2013-2016 Ebola virus (EBOV) outbreak in West Africa and the ongoing cases in the Democratic Republic of the Congo have spurred development of a number of medical countermeasures, including rapid Ebola diagnostic tests. The likelihood of transmission increases as the disease progresses due to increasing viral load and potential for contact with others. Early diagnosis of EBOV is essential for halting spread of the disease. Polymerase chain reaction assays are the gold standard for diagnosing Ebola virus disease (EVD), however, they rely on infrastructure and trained personnel that are not available in most resource-limited settings. Rapid diagnostic tests that are capable of detecting virus with reliable sensitivity need to be made available for use in austere environments where laboratory testing is not feasible. The goal of this study was to produce candidate lateral flow immunoassay (LFI) prototypes specific to the EBOV glycoprotein and viral matrix protein, both targets known to be present during EVD. The LFI platform utilizes antibody-based technology to capture and detect targets and is well suited to the needs of EVD diagnosis as it can be performed at the point-of-care, requires no cold chain, provides results in less than twenty minutes and is low cost. Monoclonal antibodies were isolated, characterized and evaluated in the LFI platform. Top performing LFI prototypes were selected, further optimized and confirmed for sensitivity with cultured live EBOV and clinical samples from infected non-human primates. Comparison with a commercially available EBOV rapid diagnostic test that received emergency use approval demonstrates that the glycoprotein-specific LFI developed as a part of this study has improved sensitivity. The outcome of this work presents a diagnostic prototype with the potential to enable earlier diagnosis of EVD in clinical settings and provide healthcare workers with a vital tool for reducing the spread of disease during an outbreak.
2013-2016 年西非埃博拉病毒(EBOV)疫情和目前刚果民主共和国的持续病例,刺激了许多医疗对策的发展,包括快速埃博拉诊断测试。由于病毒载量增加和与他人接触的可能性增加,疾病的传播可能性会增加。早期诊断 EBOV 对于阻止疾病的传播至关重要。聚合酶链反应检测是诊断埃博拉病毒病(EVD)的金标准,但是,它们依赖于基础设施和训练有素的人员,而在大多数资源有限的环境中,这些都无法提供。需要提供能够以可靠的灵敏度检测病毒的快速诊断测试,以便在实验室检测不可行的严峻环境中使用。本研究的目的是生产针对 EBOV 糖蛋白和病毒基质蛋白的候选横向流动免疫分析(LFI)原型,这两种靶标已知在 EVD 期间存在。LFI 平台利用基于抗体的技术来捕获和检测靶标,非常适合 EVD 诊断的需求,因为它可以在护理点进行,不需要冷链,在不到二十分钟内提供结果,并且成本低廉。分离、表征和评估了单克隆抗体,并在 LFI 平台中进行了评估。选择性能最佳的 LFI 原型,进一步优化并确认其对培养的活 EBOV 和受感染非人类灵长类动物的临床样本的灵敏度。与获得紧急使用批准的商业上可用的 EBOV 快速诊断测试的比较表明,作为本研究的一部分开发的糖蛋白特异性 LFI 提高了灵敏度。这项工作的结果提供了一种诊断原型,有可能在临床环境中更早地诊断 EVD,并为医疗保健工作者提供在疫情爆发期间减少疾病传播的重要工具。